John K. Moore, Director of Global Clinical Business Development at Vetter, and Patrick Meyer, Senior Director of Global Strategic Business Development at Rentschler Biopharma, sat down to talk about the alliance between the two CDMOs.
Moore and Meyer discuss how the companies plan to work together to enhance their services, offering complementary skills and experience along the biopharmaceutical value chain – from drug substance excipients all the way through commercialization.
Both companies have known each other for many years, and we share a commitment to high quality standards and value creation.
John K. Moore, Director of Global Clinical Business Development, Vetter
Our shared goal: Creating long-term value through the alignment of both CDMOs’ approaches in drug substance and drug product manufacturing, enabling biopharma customers to bring their products to patients more quickly and efficiently.
“What we see as a challenge for our customers is they want to use the highest-quality CDMOs for each step in the supply chain, whether it’s drug substance or drug product,” Moore says. “So, they need to coordinate their projects with more than one CDMO, which obviously increases their workload… We want to simplify these processes for our clients and make their lives easier.”
Watch the full interview to learn more about the goals and value of our strategic CDMO alliance.